Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Employees holding Ph.D., M.D., J.D., or Master's degrees by Year
Employees holding Ph.D., M.D., J.D., or Master's degrees (%) (%)
Moderna Employees holding Ph.D., M.D., J.D., or Master's degrees: 46.0% in FY2025, up 3.0 pts from a year earlier.
Latest, FY2025
46.0%
Period ended Dec 31, 2025
Change on a year earlier
+3.0 pts
43.0% in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“Our workforce is highly educated, and as of December 31, 2025, 46% of our employees hold Ph.D., Doctorate, M.D., J.D. or Master’s degrees.”
Source: FY2025 10-K ↗
Reported in Form 10-K Item 1 (Human Capital Management) & ESG Reports.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Employees holding Ph.D., M.D., J.D., or Master's degrees (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 46.0% | +3.0 pts | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 43.0% | +2.0 pts | FY2024 10-K ↗ |
| FY2023 | Dec 31, 2023 | 41.0% | -7.0 pts | FY2023 10-K ↗ |
| FY2022 | Dec 31, 2022 | 48.0% | +1.0 pts | FY2022 10-K ↗ |
| FY2021 | Dec 31, 2021 | 47.0% | -4.0 pts | FY2021 10-K ↗ |
| FY2020 | Dec 31, 2020 | 51.0% | 0.0 pts | FY2020 10-K ↗ |
| FY2019 | Dec 31, 2019 | 51.0% | 0.0 pts | FY2019 10-K ↗ |
| FY2018 | Dec 31, 2018 | 51.0% | – | FY2018 10-K ↗ |
Cite this data
StockData. (2026). Moderna Employees holding Ph.D., M.D., J.D., or Master's degrees (%), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/hc-adv-degrees-pct
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.